ALXO Stock Summary and Trading Ideas (Alx Oncology Holdings | NASDAQ:ALXO)

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Alx Oncology Holdings trades on the NASDAQ stock market under the symbol ALXO.

As of April 2, 2026, ALXO stock price declined to $1.97 with 398,286 million shares trading.

ALXO has a beta of 1.24, meaning it tends to be more sensitive to market movements. ALXO has a correlation of 0.03 to the broad based SPY ETF.

ALXO has a market cap of $259.27 million. This is considered a Small Cap stock.

In the last 3 years, ALXO traded as high as $17.83 and as low as $.40.

The top ETF exchange traded funds that ALXO belongs to (by Net Assets): VTI, VXF, VHT, PRFZ, AVSC.

ALXO has outperformed the market in the last year with a return of +230.8%, while the SPY ETF gained +17.5%. In the last 3 month period, ALXO beat the market returning +71.3%, while SPY returned -3.7%. However, in the most recent 2 weeks ALXO has underperformed the stock market by returning -10.0%, while SPY returned -0.1%.

ALXO support price is $1.88 and resistance is $2.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALXO shares will trade within this expected range on the day.